Expanding the Evidence on Integrated Opioid Use Disorder and Infectious Disease Care.

Low-barrier to access programs has emerged as a way to overcome the significant hurdles associated with buprenorphine initiation. However, there has been limited research evaluating services set in low-barrier programs outside of buprenorphine. In this issue of the Journal of Addiction Medicine, Harvey and colleagues evaluate a sexually transmitted and blood-borne infection screening protocol implemented in a low-barrier access program in Boston, Massachusetts. The data supports that infection protocols can be efficiently implemented in the low-barrier setting, yielding high rates of diagnosis, and the potential for decentralized models of treatment.